Predictors of survival after transarterial radioembolization in patients with hepatocellular carcinoma
Eurasian Journal of Medicine and Oncology · 16.11.2026 · 026330420
DOI: 10.36922/ejmo026330420 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eurasian Journal of Medicine and Oncology, online erschienen am 16.11.2026. Verfasst von Brian Irving Carr und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Transarterial radioembolization with yttrium-90–based microspheres (TARE) is an established therapy for patients with advanced non-metastatic hepatocellular carcinoma (HCC). However, factors associated with short or long survival are not completely clear.
Objectives
To examine a cohort of patients not candidates for surgery who were treated with TARE and had known survival duration to document and compare the characteristics of those with shorter versus longer survival times.
Methods
HCC patients (n = 308) were treated exclusively with TARE and followed until death. Their baseline and follow-up blood clinical parameters were retrospectively analyzed. Patients were categorized into short-term (11 months) survivors according to the cohort median survival.
Results
The longer- and shorter-survival groups differed significantly in maximum tumor diameter (MTD), multifocality, portal vein thrombosis (PVT), albumin-bilirubin (ALBI), modified ALBI, platelet-ALBI grades, alpha-fetoprotein (AFP), albumin, liver function parameters, and C-reactive protein. In multivariable logistic regression, MTD, multifocality, AFP, albumin, and hemoglobin had significant odds ratios. Patients with PVT were represented in both survival groups. In the longer-survival PVT group, multifocality was significantly less frequent, and MTD, platelet-ALBI grade, aspartate aminotransferase, gamma-glutamyl transferase, and C-reactive protein were lower, while albumin was higher. Increased albumin post-TARE was significantly associated with increased survival, independent of baseline AFP. Patients with normal bilirubin in the total cohort were dichotomized by albumin level. Lower albumin was associated with poorer survival and higher baseline inflammation markers, with no change in tumor factors. Increased albumin or decreased AFP post-TARE were each associated with increased survival.
Conclusion
Baseline tumor and inflammation parameters were independently associated with survival post-TARE, as were increased albumin and decreased AFP in response to TARE.
Zitieren
APA
Carr, B. I., Bag, H. G., Ramazan, K., Volkan, I., & Sezai, Y. (2026). Predictors of survival after transarterial radioembolization in patients with hepatocellular carcinoma. Eurasian Journal of Medicine and Oncology, 0(0), 026330420. https://doi.org/10.36922/ejmo026330420
Vancouver
Carr BI, Bag HG, Ramazan K, Volkan I, Sezai Y. Predictors of survival after transarterial radioembolization in patients with hepatocellular carcinoma. Eurasian Journal of Medicine and Oncology. 2026;0(0):026330420. doi:10.36922/ejmo026330420
BibTeX
@article{Carr2026,
author = {Carr, Brian Irving and Bag, Harika Gozukara and Ramazan, Kutlu and Volkan, Ince and Sezai, Yilmaz},
title = {Predictors of survival after transarterial radioembolization in patients with hepatocellular carcinoma},
journal = {Eurasian Journal of Medicine and Oncology},
year = {2026},
volume = {0},
number = {0},
pages = {026330420},
doi = {10.36922/ejmo026330420}
}
EUVIMED